ClinicalTrials.gg
CompletedNCT03154515Updated May 16, 2017

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

A Phase 4 interventional study of Ingavirin and Placebo in Common Cold, Influenza, Human and Acute Respiratory Infection, sponsored by Valenta Pharm JSC. Completed at 9 sites in Russian Federation. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-05-16.

Sponsored by Valenta Pharm JSC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 3 months after the study started (first participant enrolled Jan 2010, registered Apr 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Common Cold with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Common Cold · Russian Federation.

Enrollment
3rd of 11
445 · median 250
Started
2010
with 1 other
Phase 4
2 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
9 of 13
Valenta Pharm JSC

Among the 13 studies in Common Cold with a site in Russian Federation, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2010, is one of 2 in phase 4, and was the 4th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

1 of the 13 studies in Common Cold with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Common Cold with a site in Russian Federation, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Ingavirin® 90 mg once daily is effective and safe for the treatment of influenza and other laboratory confirmed acute respiratory viral infections in the course of standard therapy in patients 18-60 years old.

Read the detailed description

Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Ingavirin in the Treatment of Influenza and Other Acute Viral Respiratory Infection. Study treatment was 5 days followed by 2 ± 1 days of follow up period. Thus, study participation was 7 ± 1 days (8 days max).

03

Conditions studied

  • Common Cold
  • Influenza, Human
  • Acute Respiratory Infection

Keywords

  • Respiratory Tract Infections
  • Acute Respiratory Viral Infection
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically diagnosed influenza, body temperature ≥ 38 ºС or other acute respiratory viral infection, body temperature ≥ 37 ºС, with no less than 2 symptoms of catarrhal and intoxication each:

    • Intoxication symptoms: Dizziness, headache, chills, fever, sweating, fatigue, myalgia, pain while moving eyes, flushing, pale skin, sleep disturbances, decreased appetite, nausea, vomiting, epistaxis, cyanosis, meningeal signs.
    • Catarrhal symptoms: Sore throat, rhinorrhea and nasal congestion, difficulty swallowing, hoarseness, stridor, wheezing, rattling dry and wet cough, expectoration.
  • Laboratory confirmation of viral origin of the disease
  • Uncomplicated influenza and other acute respiratory viral infections
  • Interval between onset of symptoms and enrollment to the study not more than 48 hours
  • Have read, understood and signed an form

Exclusion criteria

Exclusion Criteria:

  • Complicated course of influenza and other acute respiratory viral infections (secondary bacterial infection)
  • Pregnancy and Breastfeeding
  • Severe decompensated or unstable medical or psychiatric conditions (any diseases or conditions that threaten the life of the patient or worsen the patient's prognosis)
  • Cancer, infection, tuberculosis, including those in history
  • History of alcohol and drug abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
445 participants (actual)

Study arms

  • Experimental
    Ingavirin

    Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days

    Drug: Ingavirin

  • Placebo comparator
    Placebo

    Placebo capsule identical in appearance to Ingavirin capsule

    Drug: Placebo

Interventions

  • Also known as: Imidazolyl ethanamide pentandioic acid

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Time to resolution of fever

    Time from the start of study treatment to resolution of fever ( t ≤ 36,9 ºС, till the end of the follow up).

    Time frame: 7 ± 1 days

Secondary outcomes

  1. Time to resolution / alleviation of intoxication symptoms

    Following symptoms were recorded and rated each visit, to evaluate symptoms progress: Dizziness, headache, chills, fever, sweating, fatigue, myalgia, pain while moving eyes, flushing, pale skin, sleep disturbances, decreased appetite, nausea, vomiting, epistaxis, cyanosis, meningeal signs.

    Time frame: 7 ± 1 days

  2. Time to resolution / alleviation of catarrhal symptoms

    Following symptoms were recorded and rated each visit, to evaluate symptoms progress: Sore throat, rhinorrhea and nasal congestion, difficulty swallowing, hoarseness, stridor, wheezing, rattling dry and wet cough, expectoration.

    Time frame: 7 ± 1 days

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    All adverse events recorded and analysed, to compare incidence rate with one of placebo. Complete blood count test performed at the beginning and at the end of the study. Vital signs taken and recorded at each visit throughout the study, usually every day for 7 ± 1 days.

    Time frame: Through study completion, an average of 8 days

07

Study locations

9 sites
  • State educational institution of higher professional education "Chelyabinsk State Medical Academy of Federal Agency of Health Care and Social Development"
    Chelyabinsk, 454092, Russian Federation
  • N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology
    Moscow, 123098, Russian Federation
  • State budgetary health care institution novosibirsk region "city clinical infectious diseases hospital no. 1"
    Novosibirsk, Russian Federation
  • North-western State Medical University named after I.I.Mechnikov
    Saint Petersburg, 195067, Russian Federation
  • Saratov State Medical University named after V. I. Razumovsky
    Saratov, 410012, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Pacific State Medical University" of the Ministry of Healthcare of the Russian Federation
    Vladivostok, 690002, Russian Federation
  • Volgograd State Medical University
    Volgograd, 400131, Russian Federation
  • Yaroslavl State Medical University
    Yaroslavl, 150000, Russian Federation
  • Federal State Budgetary Institution of Higher Professional Education "Urals State Medical University" of the Ministry of Healthcare of the Russian Federation
    Yekaterinburg, 620028, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in Apr 2014, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2017
First posted
May 16, 2017
StartActual
Jan 2010
Primary completionActual
Apr 2014
CompletionActual
Oct 2014
Last update
May 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03154515
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
May 16, 2017
Start date
Jan 2010
Primary completion
Apr 2014
Completion
Oct 2014
Last update
May 16, 2017

Study contacts

Ekaterina Zakharova, MD, PhD
study director · Valenta Pharm JSC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion